Börje Ekholm Nominated as New Chair for Sobi's Board of Directors in 2027

Sobi's Board of Directors Nominations

In a significant development for Swedish Orphan Biovitrum AB, commonly known as Sobi, Börje Ekholm has been proposed as the new Chair of the Board of Directors. This decision comes as current Chair David Meek announced that he will not seek re-election at the upcoming 2027 Annual General Meeting (AGM).

David Meek, who has served on Sobi's Board since December 2024 and as Chair since then, will continue fulfilling his duties until May 2027. Under his leadership, Sobi has experienced substantial growth, broadening access to its innovative medicines through various product launches and indication expansions. His focus has been on reinforcing the clinical development pipeline, which is critical for the company’s long-term ambitions.

Börje Ekholm's Background

Börje Ekholm is no stranger to heavy-hitting leadership roles, boasting over three decades of experience in technology, investment management, and international business. He recently concluded his tenure as the CEO of Ericsson, a pivotal position that has equipped him with insights into the evolving technological landscape. Beyond Ericsson, he held the CEO title at Patricia Industries and Investor AB.

As a current Chair for Trimble Inc. and a newly appointed Board member of Nasdaq Inc., commencing November 1, 2026, Ekholm's extensive board experience is particularly valuable. His previous responsibilities include key roles with well-known companies such as Alibaba, Husqvarna, and Scania, where he also served as Chair.

During his time at Investor, Ekholm played an instrumental role in Sobi's establishment by overseeing the merger between Biovitrum and Swedish Orphan International. His familiarity with Sobi from an ownership perspective gives him unique insights into its operations and strategic objectives.

Remarks from the Nomination Committee

Daniel Nodhäll, Chair of the Nomination Committee, expressed enthusiasm about the proposal, noting, "We are pleased to propose Börje Ekholm as the new Chair of the Sobi Board. Börje has significant global leadership and board experience and is very familiar with the company." Nodhäll also conveyed gratitude to Meek for his successful leadership and the strong performance of the company during his tenure.

Looking Ahead

The Nomination Committee's full slate of proposals is set to be disclosed in due time before the AGM. This transition of leadership at Sobi is anticipated to usher in new strategies and enhanced performances, further cementing Sobi's position in the biopharmaceutical landscape.

Sobi is recognized for developing therapeutic solutions that significantly improve the quality of life for individuals battling rare diseases. With around 2,000 employees distributed across multiple regions, the company generated substantial revenue of SEK 28 billion in 2025. The upcoming changes in leadership are poised to steer Sobi into its next growth phase, with Ekholm at the helm.